104 related articles for article (PubMed ID: 11669508)
1. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U
Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
[TBL] [Abstract][Full Text] [Related]
3. The effects of different acetylcholinesterase inhibitors on EEG patterns in patients with Alzheimer's disease: A systematic review.
Arjmandi-Rad S; Vestergaard Nieland JD; Goozee KG; Vaseghi S
Neurol Sci; 2024 Feb; 45(2):417-430. PubMed ID: 37843690
[TBL] [Abstract][Full Text] [Related]
4. Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Soysal P; Isik AT
J Nutr Health Aging; 2016 Apr; 20(4):398-403. PubMed ID: 26999239
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials in mild cognitive impairment: lessons for the future.
Jelic V; Kivipelto M; Winblad B
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):429-38. PubMed ID: 16306154
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
Przybyłowska M; Dzierzbicka K; Kowalski S; Chmielewska K; Inkielewicz-Stepniak I
Curr Neuropharmacol; 2021; 19(8):1323-1344. PubMed ID: 33342413
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia.
Droogsma E; van Asselt DZ; van Steijn JH; Schuur T; Huinink EJ
J Nutr Health Aging; 2013; 17(5):461-5. PubMed ID: 23636548
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.
Wang J; Zhang HY; Tang XC
Acta Pharmacol Sin; 2009 Jul; 30(7):879-88. PubMed ID: 19574993
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia.
Lim EY; Yang DW; Kim JS; Cho AH
J Korean Med Sci; 2018 May; 33(19):e133. PubMed ID: 29736156
[TBL] [Abstract][Full Text] [Related]
10. An innovative approach to involve patients in measuring treatment effects in drug trials.
Kaduszkiewicz H
CMAJ; 2006 Apr; 174(8):1117-8. PubMed ID: 16554497
[No Abstract] [Full Text] [Related]
11. Rehabilitating a brain with Alzheimer's: a proposal.
Aranda-Abreu GE; Hernández-Aguilar ME; Manzo Denes J; García Hernández LI; Herrera Rivero M
Clin Interv Aging; 2011; 6():53-9. PubMed ID: 21472092
[TBL] [Abstract][Full Text] [Related]
12. Review of issue: studies on veterans, a useful pain scale, and plasma amyloid levels as a predictor of response to medications.
Lippa CF
Am J Alzheimers Dis Other Demen; 2008; 23(3):215-7. PubMed ID: 18646293
[No Abstract] [Full Text] [Related]
13. Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease.
Kano O; Urita Y; Ito H; Takazawa T; Kawase Y; Murata K; Hirayama T; Miura K; Ishikawa Y; Kiyozuka T; Aoyagi J; Iwasaki Y
Neuropsychiatr Dis Treat; 2013; 9():1411-5. PubMed ID: 24092978
[TBL] [Abstract][Full Text] [Related]
14. Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil.
Kano O; Ito H; Takazawa T; Kawase Y; Murata K; Iwamoto K; Nagaoka T; Hirayama T; Miura K; Nagata R; Kiyozuka T; Aoyagi J; Sato R; Eguchi T; Ikeda K; Iwasaki Y
Neuropsychiatr Dis Treat; 2013; 9():259-65. PubMed ID: 23431041
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions.
Marksteiner J; Schmidt R
Drugs Aging; 2004; 21(7):415-26. PubMed ID: 15132710
[TBL] [Abstract][Full Text] [Related]
16. Maintaining functional and behavioral abilities in Alzheimer disease.
Winblad B
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S34-40. PubMed ID: 11669508
[TBL] [Abstract][Full Text] [Related]
17. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
Blesa R
Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
[TBL] [Abstract][Full Text] [Related]
18. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
19. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Bullock R; Connolly C
Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
